TaiGen Biopharmaceuticals Holdings Limited announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 1,244.487 million compared to TWD 7.498 million a year ago. Operating income was TWD 1,122.654 million compared to operating loss of TWD 60.099 million a year ago. Net income was TWD 1,100.459 million compared to net loss of TWD 102.936 million a year ago. Basic earnings per share was TWD 1.54 compared to basic loss per share of TWD 0.14 a year ago. Diluted earnings per share was TWD 1.53. For the half year, sales was TWD 1,290.637 million compared to TWD 10.819 million a year ago. Operating income was TWD 1,088.972 million compared to operating loss of TWD 112.944 million a year ago. Net income was TWD 1,056.805 million compared to net loss of TWD 175.113 million a year ago. Basic earnings per share was TWD 1.47 compared to basic loss per share of TWD 0.24 a year ago. Diluted earnings per share was TWD 1.47.